Vertex Pharmaceuticals (VRTX) Invested Capital (2009 - 2017)

Vertex Pharmaceuticals' Invested Capital history runs 14 years deep, the most recent figure standing at $118.0 million for Q4 2024.

• In Q4 2024, Invested Capital fell 72.35% year-over-year to $118.0 million; the TTM figure through Sep 2025 stood at $118.0 million (down 78.38% YoY), while the FY2024 annual figure was $118.0 million, down 72.35% from the prior year.
• Invested Capital for Q4 2024 stood at $118.0 million, down from $119.1 million in the prior quarter.
• The five-year high for Invested Capital was $581.5 million in Q4 2020, with the low at $118.0 million in Q4 2024.
• The 5-year median for Invested Capital is $449.2 million (2022), against an average of $378.9 million.
• The sharpest annual moves came in 2020 and 2024: Invested Capital gained 0.72% in 2020, then slumped 72.35% in 2024.
• Vertex Pharmaceuticals' Invested Capital stood at $581.5 million in 2020, then declined by 4.26% to $556.7 million in 2021, then decreased by 15.29% to $471.6 million in 2022, then slipped by 9.52% to $426.7 million in 2023, then plunged by 72.35% to $118.0 million in 2024.
• Business Quant data shows VRTX's Invested Capital at $118.0 million in Q4 2024, $119.1 million in Q3 2024, and $426.7 million in Q4 2023.